Ganoderma lucidum as a Cancer Adjunct: Clinical Evidence

Reishi and Cancer Research

HR 0.82 mortality risk

In a 2019 meta-analysis of randomized controlled trials, GL-related products were associated with lower mortality risk and 30% higher treatment efficacy compared to standard care alone.

Zhong et al., Frontiers in Pharmacology, 2019

1.27×

tumor response enhancement vs. chemo/radiotherapy alone, Cochrane 2016 (5 RCTs, n=373)

RR 2.51

higher rate of Karnofsky QOL improvement with GL vs. without, Cochrane 2016

65%

of advanced lung cancer patients showed Karnofsky score improvement on GL polysaccharides, Gao 2005

Zhong et al., Frontiers in Pharmacology, 2019

View as image ↗

Most writing about reishi mushroom and cancer hedges toward "shows promise in preliminary research" and points readers to the Cochrane review finding on quality of life improvement. The Cochrane data is real and worth understanding. But it is not the strongest piece of clinical evidence for Ganoderma lucidum as a cancer adjunct.

That distinction belongs to a 2019 meta-analysis by Zhong and colleagues, which analyzed data from multiple randomized controlled trials and found GL-related products associated with a statistically significant reduction in mortality risk (hazard ratio 0.82; 95% CI 0.72 to 0.94) and a 30% higher treatment efficacy rate compared to standard care alone (RR 1.30; 95% CI 1.09 to 1.55).^[1] An HR of 0.82 means patients receiving GL alongside standard treatment had an 18% lower relative risk of dying during the study period compared to those receiving standard treatment only. That is not a cell line result. That is from controlled clinical trials in cancer patients.

This article covers what the human studies show, what they don't show, how GL interacts with conventional chemotherapy at the cellular level, and what the emerging 2024 research on GL and modern immunotherapy represents. For the broader biology and mechanism context, see the complete reishi guide.

Ganoderma lucidum as Cancer Adjunct Therapy: What the RCTs Show

The strongest evidence for reishi as a cancer adjunct therapy comes from two aggregate analyses of controlled trials conducted roughly a decade apart.

The 2016 Cochrane review by Jin and colleagues analyzed 5 randomized controlled trials involving 373 total cancer patients.^[2] Two primary findings drove the review's conclusions. First, GL patients were 2.51 times more likely to show improvement in Karnofsky performance scores (a measure of functional ability in cancer patients, from unable to care for self to fully active) compared to controls (RR 2.51; 95% CI 1.86 to 3.40). Second, patients receiving GL alongside chemotherapy or radiotherapy showed 1.27 times greater tumor response compared to those receiving chemo/radio alone. The review's honest conclusion was that the evidence supported GL as an adjunct, not a standalone treatment, and that more rigorously designed RCTs with standardized extracts were needed to establish dose-response relationships.

The first Cochrane version, published in 2012, had analyzed 3 of these same trials with comparable findings, providing an earlier anchor for the QOL improvement conclusion.^[3]

Zhong and colleagues' 2019 meta-analysis added the dimension the Cochrane review lacked: mortality data.^[1] The HR 0.82 result is the most clinically meaningful number in the entire GL cancer literature. Quality of life improvements and tumor response rates matter, but mortality reduction matters more. That no consumer health article leads with the Zhong 2019 mortality data, instead focusing only on the QOL findings that Cochrane made famous, represents a significant gap in public understanding of what the controlled trial evidence actually shows.

A 2020 narrative review by Jeitler and colleagues, specifically examining medicinal mushrooms in integrative oncology, assessed GL as having the strongest clinical evidence among all medicinal mushrooms reviewed for quality of life outcomes in cancer patients.^[4] The review documented NK cell activation, T-lymphocyte enhancement, and fatigue reduction as the most consistently reported outcomes across clinical studies.

The Most Direct Human Evidence: Studies Measuring Actual Patient Outcomes

Two studies provide the most direct human evidence: one measuring immune marker changes in cancer patients, one an actual randomized controlled trial with validated outcome measures.

Gao and colleagues' 2005 study enrolled 34 patients with advanced lung cancer and administered GL polysaccharides at 1,800 milligrams per day for 12 weeks.^[5] At 12 weeks, CD3 and CD4 T cell counts had significantly increased, NK cell activity was significantly elevated, and Karnofsky performance scores improved in 65% of patients. These are not patient-reported endpoints alone. They are measurable changes in immune cell populations from blood samples taken before and after supplementation. The study showed that GL polysaccharides at clinically relevant doses change the immune profile of human cancer patients in directions consistent with the preclinical mechanism research. The study was small and unblinded, which limits how much weight to put on each specific result, but it is one of very few human studies with actual immune marker data.

Zhao and colleagues' 2012 RCT remains the most methodologically rigorous single study in the GL cancer adjunct literature.^[6] It enrolled 48 breast cancer patients currently receiving endocrine therapy (hormonal treatment), randomized them to GL spore powder (1,000 mg/day) or placebo for four weeks, and used the EORTC QLQ-C30 (a validated quality of life measure designed for oncology research) as the primary outcome instrument. GL spore powder significantly improved cancer-related fatigue, reduced anxiety and depression scores, and improved sleep quality and appetite compared to placebo. These are validated, patient-reported outcomes measured with an instrument designed specifically for cancer clinical research, in a blinded randomized design, in a population commonly seeking this kind of supplemental support.

For more on GL research specifically in breast cancer patients, see Reishi and Breast Cancer: Research on Hormone-Sensitive Tumors.

The 4,149-Patient Counterpoint: When the Picture Is Mixed

Bao and colleagues' 2012 analysis provides the most important honest counterpoint in this literature, and it is almost never cited by health content writers.^[7] The Shanghai Breast Cancer Survival Study enrolled 4,149 breast cancer survivors and recorded supplement use and quality of life outcomes at multiple follow-up timepoints. Within this cohort, 58.8% reported using GL products within 6 months of their cancer diagnosis.

The results were not what advocates would choose to highlight. GL use was associated with better scores on the social well-being subscale (social functioning, emotional support). But it was also associated with worse scores on the physical well-being subscale (fatigue, pain, physical function). There was no significant association with overall quality of life. The study was observational, which means causation cannot be established from it; GL users may have been sicker to begin with, which could explain the physical well-being finding. But the result illustrates why single QOL studies, even large ones, are difficult to interpret for this population.

The honest reading of the combined evidence: the Zhao 2012 RCT in a specific, defined population (endocrine therapy patients) showed clear benefit. The Bao 2012 observational cohort in a broader population showed mixed results. Both findings are part of the evidence base, and omitting the Bao data in favor of only reporting positive results is exactly the kind of selectivity that makes health content untrustworthy.

How GL Works Alongside Chemotherapy: Two Distinct Mechanisms

Understanding why GL might enhance cancer treatment efficacy requires understanding how it interacts with chemotherapy at the cellular level. Two mechanisms have been characterized in research.

The first is immune enhancement. Guggenheim and colleagues' 2014 review of mushroom compounds in integrative oncology documented GL polysaccharides activating NK cells via the dectin-1 and TLR4 pathways, increasing interferon-gamma production, and enhancing the CD4 to CD8 T cell ratio.^[8] Importantly, the review also documented that GL polysaccharides upregulate MHC class I expression on tumor cell surfaces. MHC class I molecules are the identification markers that allow cytotoxic T cells and NK cells to recognize and kill a cell as abnormal. Many tumor cells evade immune detection by downregulating MHC class I expression. GL polysaccharides partially reverse this evasion tactic, making tumor cells more visible to the immune system's surveillance.

The second mechanism is chemosensitization. Suárez-Arroyo and colleagues' 2022 research found that GL extract sensitized ovarian cancer cells to carboplatin (a platinum-based chemotherapy drug) by a distinct pathway.^[9] Carboplatin kills cancer cells by inducing DNA damage. Cancer cells can resist this by activating the DNA damage response pathway (via the kinases ATM, Chk1, and Chk2), which detects and repairs the damage before it kills the cell. GL extract inhibited this repair pathway, preventing cancer cells from fixing the chemo-induced DNA breaks. In mouse xenograft models, the combination of GL plus carboplatin produced greater tumor regression than carboplatin alone. This mechanism is not about immune activation. It is about blocking cancer cells' molecular defense against chemotherapy. Neuwirthová and colleagues' 2020 clinical guidance review for oncologists drew on this mechanistic evidence base to characterize GL as a meaningful complement to conventional cancer treatment, not a replacement.^[10]

For a deeper exploration of how GL polysaccharides and triterpenoids complement each other in these mechanisms, see Reishi Polysaccharides and Tumor Immune Surveillance and Ganoderic Acids and Cancer: Specific Anti-Tumor Research.

The 2024 Research: GL Compounds and Modern Immunotherapy

The most consequential recent development in GL cancer research is the discovery that ganoderic acid T interacts with the tumor microenvironment in a way that may enhance checkpoint inhibitor therapy.

Chen and colleagues' 2024 study found that ganoderic acid T (GA-T) reduced the expression of galectin-1 in tumor tissue.^[11] Galectin-1 is a protein that tumor cells use to suppress the immune response within the tumor microenvironment, and it is one of the mechanisms by which tumors hide from immune attack even in patients undergoing checkpoint inhibitor therapy. By reducing galectin-1, GA-T reversed a component of the tumor's immune suppression. When the researchers combined GA-T with an anti-PD-1 checkpoint inhibitor antibody in mouse tumor models, antitumor efficacy was significantly greater than either treatment alone. This is the first research to directly connect a specific GL compound (a ganoderic acid) to the mechanism underlying checkpoint inhibitor therapy.

Checkpoint inhibitors (anti-PD-1, anti-CTLA-4, and related drugs) represent a major paradigm in modern oncology, with approvals across multiple cancer types. The finding that a GL triterpenoid may potentiate their effect by addressing a complementary immunosuppressive mechanism is scientifically meaningful. It is also entirely preclinical. Chen et al.'s work was in mouse models, not human patients, and the step from mouse models to human clinical trials is large. But this finding represents the first plausible mechanism connecting GL to the most important treatment advance in oncology of the past decade.

Abdelmoaty and colleagues' 2024 research identified a separate new angle: GL triterpenoid complex may eliminate treatment-resistant cancer cells via senolytic activity.^[12] Chemotherapy can induce cancer cells into a senescent state (a kind of cellular dormancy where the cell stops dividing but also resists death). These senescent cancer cells accumulate during treatment and are associated with drug resistance and cancer recurrence. GL triterpenoid complex demonstrated the ability to selectively clear these senescent cancer cells, a senolytic mechanism not previously associated with mushroom compounds. If this translates to clinical relevance, it would represent a second distinct mechanism by which GL complements rather than duplicates chemotherapy's effects.

Safety During Cancer Treatment: What the Evidence Shows

Cancer patients considering GL supplementation alongside standard treatment need accurate safety information.

Thuy and colleagues' 2023 systematic review of GL spore-specific pharmacological activities identified two primary safety signals.^[13] First, the general safety profile of GL spore preparations is good, consistent with the Cochrane review's confirmation of no major adverse effects at standard doses. Second, hepatotoxicity risk (elevated liver enzymes or in rare cases liver damage) has been identified primarily with spore-based products at high doses used for extended periods.

Narayanan and colleagues' 2023 systematic review of clinical studies on medicinal mushroom supplements in cancer confirmed this pattern: across the GL clinical literature, safety was generally acceptable at standard supplement doses, with the most consistent concern being hepatotoxicity at high doses or prolonged use.^[14] The review also noted that GL's immunostimulatory effects create a theoretical concern for patients on immunosuppressive therapy, including organ transplant recipients or patients with autoimmune disease being treated alongside their cancer.

The practical implication: at doses studied in clinical trials (1,000 to 1,800 mg/day of standardized extract for periods of 4 to 12 weeks), the safety record is generally clean. Extended high-dose use, particularly with spore preparations, warrants attention to liver function. Patients on concurrent immunosuppressive medications and those receiving immunotherapy should consider that GL's immunostimulatory activity could interact with both in ways that require physician involvement rather than self-dosing decisions.

For a comprehensive look at the research specifically in the tumor biology context, see Reishi and Cancer: What 50 Years of Research Tells Us. For the prostate cancer-specific evidence, see Reishi and Prostate Cancer: Ganoderic Acid Research.

The Bottom Line

The clinical evidence for Ganoderma lucidum as a cancer adjunct therapy is more substantial than most consumer health content represents. The Zhong 2019 meta-analysis found HR 0.82 mortality reduction and 1.30× treatment efficacy improvement in RCTs. The 2016 Cochrane review confirmed Karnofsky QOL improvement (RR 2.51) and 1.27× tumor response enhancement. The most rigorous single trial (Zhao 2012, n=48) demonstrated significant fatigue and mood improvement in breast cancer patients on endocrine therapy. The honest counterpoint: Bao 2012 found mixed QOL results in 4,149 women. Mechanistically, GL polysaccharides enhance immune surveillance and sensitize tumors to chemotherapy; the 2024 research connects ganoderic acid T to checkpoint inhibitor potentiation via galectin-1 suppression. Safety is generally good at standard doses, with hepatotoxicity risk at prolonged high doses.

Frequently Asked Questions

Can Ganoderma lucidum be used alongside chemotherapy?

The clinical evidence supports GL as an adjunct to chemotherapy, not a replacement. The 2016 Cochrane review of 5 RCTs (n=373) found GL patients showed 1.27× greater tumor response when combined with chemotherapy or radiotherapy vs. standard treatment alone. Suárez-Arroyo 2022 identified a chemosensitization mechanism: GL inhibits the DNA damage repair pathway that cancer cells use to resist chemotherapy. Safety monitoring for liver function is warranted at higher doses, and patients on concurrent immunosuppressive therapy should involve their physician.

Does reishi mushroom improve quality of life in cancer patients?

Yes, with a nuanced picture. The Cochrane 2016 review found GL patients 2.51 times more likely to show Karnofsky performance score improvement compared to controls. The Zhao 2012 RCT (n=48) specifically found GL spore powder significantly reduced fatigue, anxiety, depression, and sleep problems in breast cancer patients on endocrine therapy. However, Bao 2012 in 4,149 Shanghai breast cancer survivors found GL use associated with better social well-being but worse physical well-being, with no significant overall QOL benefit, a large observational study with mixed results that most articles don't report.

What clinical trials exist for Ganoderma lucidum and cancer?

The main clinical evidence comes from 5 RCTs analyzed in the 2016 Cochrane review (n=373 total), plus the Zhao 2012 breast cancer RCT (n=48), the Gao 2005 lung cancer cohort (n=34), and the Bao 2012 observational cohort (n=4,149). The Zhong 2019 meta-analysis combined RCT data to find HR 0.82 for mortality risk. A 2023 systematic review by Narayanan confirmed that reishi is among the most-studied medicinal mushrooms in clinical oncology. Consistent limitation across studies: heterogeneous extract types, variable doses, and lack of standardized protocols make direct comparison across trials difficult.

Does reishi mushroom enhance the effects of chemotherapy?

Preclinical and clinical evidence suggests it can in at least two distinct ways. First, GL polysaccharides activate NK cells and upregulate MHC class I expression on tumor cells (making them more visible to immune surveillance), identified in the Guggenheim 2014 review. Second, GL extract inhibits the ATM/Chk1/Chk2 DNA damage response pathway that cancer cells use to repair chemo-induced DNA breaks, re-sensitizing resistant cells to carboplatin in Suárez-Arroyo 2022. The 2019 Zhong meta-analysis found 30% higher treatment efficacy when GL was combined with standard care in human clinical trials.

Is Ganoderma lucidum safe to take during cancer treatment?

At doses used in clinical trials (1,000 to 1,800 mg/day of standardized extract for 4 to 12 weeks), the safety record is generally good. The 2016 Cochrane review confirmed no major adverse effects in its RCT dataset. The main identified risk is hepatotoxicity, primarily with spore-based products at high doses over extended periods, confirmed in the Thuy 2023 systematic review of GL spore safety. Patients on immunosuppressive medications, immunotherapy, or those with existing liver conditions should involve their oncologist before using GL, as its immunostimulatory activity can interact with both.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9. Source details for this reference are not yet available.
10. 10. Source details for this reference are not yet available.
11. 11. Source details for this reference are not yet available.
12. 12. Source details for this reference are not yet available.
13. 13. Source details for this reference are not yet available.
14. 14. Source details for this reference are not yet available.